Autologous hematopoietic stem cell transplantation is one of the effective means of lymphoma
treatment, but patients who receive transplantation in the absence of sufficient stem cell
numbers have a delay in stem cell engraftment and a markedly increased risk of infection and
emergence. Plerixafor injection is a strong and specific antagonist of CXCR4. It can rapidly
mobilize stem cells from bone marrow into peripheral blood circulation by blocking the
combination of SDF1 and CXCR4. Studies have shown that the simultaneous use of plerixafor
injection and G-CSF can collect more hematopoietic stem cells in a certain period of time
than cancer patients who use G-CSF alone. This multicenter, open-label, single-arm study was
designed to evaluate the efficacy and safety of plerixafor injection for hematopoietic stem
cell mobilization in poorly mobilized lymphoma patients.